Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688796's PB Ratio is ranked worse than 86.09% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs SHSE:688796: 9.56
During the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co's average Book Value Per Share Growth Rate was 141.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 19.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -2.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Biocytogen Pharmaceuticals (Beijing) Co was 19.10% per year. The lowest was -20.80% per year. And the median was -16.50% per year.
Back to Basics: PB Ratio
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Related Terms
Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
SHSE:688796 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co PB Ratio vs Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a PB Ratio of 24.47 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. This is 269% above median its historical median of 6.64. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio has ranged from 2.63 to 15.63. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #1058 out of 1229 companies in the Biotechnology industry, placing it in the top 86.1%.
Is Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio too high?
Biocytogen Pharmaceuticals (Beijing) Co's current PB Ratio of 24.47 is 269% above median its 10-year median of 6.64. Over the past 10 years, this metric has ranged from a low of 2.63 to a high of 15.63. The Biotechnology industry median PB Ratio is 2.79. Biocytogen Pharmaceuticals (Beijing) Co's value of 24.47 is 777.1% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #1058 out of 1229 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #1058 out of 1229 companies for PB Ratio. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median PB Ratio is 2.79. Biocytogen Pharmaceuticals (Beijing) Co's value of 24.47 is 777.1% above this benchmark. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own PB Ratio has ranged from 2.63 to 15.63 over the past decade. While the company's 10-year median is 6.64 vs. the industry median of 2.79, Biocytogen Pharmaceuticals (Beijing) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current PB Ratio of 24.47 is 777.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current PB Ratio is 24.47, which is 269% above median its own 10-year median of 6.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥74.57, compared to a current price of ¥120.00 — trading 60.9% above its estimated fair value. The current PB Ratio is 24.47, which is 269% above median its 10-year median of 6.64 and 777.1% above the Biotechnology industry median of 2.79. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current PB Ratio is 24.47 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of ¥120.00 is trading 60.9% above its estimated GF Value™ of ¥74.57.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for SHSE:688796:
PB Ratio: 24.47 (269% above median its 10-year median of 6.64)
GF Value™: ¥74.57 vs. price of ¥120.00 (60.9% above fair value)
Industry Position: 777.1% above the Biotechnology median (#1058 of 1229)
No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
52GF Score
Get the complete analysis for SHSE:688796
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688796 has been successfully added to your 
